Interestingly, although the recognition is not yet as well described as for the ACPA, studies of monoclonal anti-MDA/MAA antibodies from RA patients show that these autoantibodies also display a multireactivity to different modified proteins. This evidence concerns the gene PRTN3 and rheumatoid arthritis.